Primary Central Nervous System Lymphoma Pcnsl clinical trials

Explore recruiting primary central nervous system lymphoma pcnsl clinical trials.

Recruiting primary central nervous system lymphoma pcnsl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Central Nervous System Lymphoma Pcnsl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Czechia, Germany, Italy, Belgium, Spain, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Pilot-trial of methotrexate, tafasitamab (Minjuvi®), lenalidomide (Revlimid®) and rituximab in patients ineligible for HCT-ASCT with primary central nervous system lymphoma (PCNSL) -MTR²

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Poland, France, Spain, Czechia, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Primary Central Nervous System Lymphoma Pcnsl trials by city

Primary Central Nervous System Lymphoma Pcnsl in Toronto Primary Central Nervous System Lymphoma Pcnsl in Vancouver Primary Central Nervous System Lymphoma Pcnsl in Montreal Primary Central Nervous System Lymphoma Pcnsl in Calgary Primary Central Nervous System Lymphoma Pcnsl in Edmonton Primary Central Nervous System Lymphoma Pcnsl in Ottawa Primary Central Nervous System Lymphoma Pcnsl in Winnipeg Primary Central Nervous System Lymphoma Pcnsl in Quebec City Primary Central Nervous System Lymphoma Pcnsl in Hamilton Primary Central Nervous System Lymphoma Pcnsl in Kitchener Primary Central Nervous System Lymphoma Pcnsl in London Primary Central Nervous System Lymphoma Pcnsl in Halifax Primary Central Nervous System Lymphoma Pcnsl in New York Primary Central Nervous System Lymphoma Pcnsl in Los Angeles Primary Central Nervous System Lymphoma Pcnsl in Chicago Primary Central Nervous System Lymphoma Pcnsl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease